Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement

Kim, Seon Young; Kim, Hyo Jung; Kang, Hye Jin; Kim, Jin Seok; Eom, Hyeon Seok; Kim, Tae Min; Yoon, Sung-Soo; Suh, Cheolwon; Lee, Dong Soon

doi:10.1186/1756-8722-6-76

Table 5 Multivariate Cox analysis of the overall survival (OS) and progression-free survival (PFS) among 327 patients having either cytogenetic abnormalities (CAs) or histologic BM involvement (BMI _histo ⁺ ) and among R-CHOP treated patients (n = 200) ^*

From: Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement

		OS			PFS
Risk factors	No. of patients (%)	HR	95% CI	P	HR	95% CI	P
Total patients with CAs and/or BMI _histo ⁺ (n = 327)
Presence of ≥ 2 cytogenetic abnormalities as a risk factor
IPI risk group, high vs. low	123 (37.6)	6.46	1.56-26.72	0.010	7.15	1.73-29.46	0.007
R-CHOP treatment, R-CHOP vs. others	200 (61.2)	0.26	0.18-0.35	<0.001	0.38	0.28-0.51	<0.001
≥ 2 cytogenetic abnormalities vs. 0 or 1 abnormality	138 (42.2)	2.49	1.75-3.54	<0.001	2.12	1.53-2.93	<0.001
Presence of specific cytogenetic abnormalities as risk factors
IPI risk group, high vs. low	123 (37.6)	8.34	2.04-24.09	0.003	8.43	2.06-34.44	0.003
R-CHOP treatment, R-CHOP vs. others	200 (61.2)	0.24	0.17-0.34	<0.001	0.32	0.24-0.44	<0.001
19p13 abnormality present vs. absent	24 (7.3)	2.67	1.50-4.76	0.001	3.02	1.85-4.93	<0.001
7q22 abnormality present vs. absent	11 (3.4)	3.03	1.51.-6.06	0.002	NS	NS	NS
12q22-q24 abnormality present vs. absent	12 (3.7)	2.68	1.37.-5.26	0.004	NS	NS	NS
18q21 abnormality present vs. absent	21 (6.4)	2.11	1.22.-3.64	0.007	NS	NS	NS
16q22-q24 abnormality present vs. absent	14 (4.3)	2.27	1.23-4.18	0.009	NS	NS	NS
11q23-q25 abnormality present vs. absent	19 (5.8)	1.81	1.03-3.15	0.038	NS	NS	NS
8q24 abnormality present vs. absent	19 (5.8)	NS	NS	NS	2.61	1.54-4.43	<0.001
R-CHOP treated patients with CAs and/or BMI _histo ⁺ (n = 200)
Presence of ≥ 2 cytogenetic abnormalities as a risk factor
IPI risk group, high vs. low	67 (33.5)	5.29	1.23-22.86	0.026	5.55	1.32-23.37	0.020
Male vs. female	112 (56.0)	1.71	1.01-2.91	0.046	NS	NS	NS
≥ 2 cytogenetic abnormalities vs. 0 or 1 abnormality	78 (39.0)	2.01	1.17-3.45	0.012	2.15	1.38-3.38	0.001
Presence of specific cytogenetic abnormalities as risk factors
IPI risk group, high vs. low	67 (33.5)	5.92	1.40-25.04	0.016	7.61	1.82-31.92	0.006
Male vs. female	112 (56.0)	2.00	1.15-3.47	0.014	1.71	1.09-2.69	0.021
19q13 abnormality present vs. absent	13 (6.5)	3.36	1.50-7.54	0.003	NS	NS	NS
12q22-q24 abnormality present vs. absent	6 (3.0)	3.65	1.42-9.44	0.007	NS	NS	NS
19p13 abnormality present vs. absent	16 (8.0)	2.85	1.20-6.80	0.018	3.31	1.68-6.51	0.001
8q24 abnormality present vs. absent	13 (6.5)	2.54	1.24-5.23	0.011	2.43	1.24-4.73	0.009

*The multivariate Cox regression models initially included age, gender, the International Prognostic Index (IPI) risk groups, history of R-CHOP treatment, presence of histologic bone marrow involvement, and either presence of ≥ 2 cytogenetic abnormalities, or presence of specific cytogenetic abnormalities found in minimum 5 R-CHOP-treated patients and associated with significant poor prosnosis in the univariate analysis (+3, -17, abnormalities at 14q32, 3q25-q27, 19p13, 8q24, 7q22, 1q21-q23, 18q21, 19q13, 9q34, 22q11, 11q23-q25, 12q22-q24, 16q22-q24, and deletion 6q). The stepwise selection procedure was used to select variables in the final models.
Abbreviations: CI, confidence interval; HR, hazard ratio; NS, not significant.

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com

Journal of Hematology & Oncology

Contact us